Matches in Nanopublications for { ?s ?p "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP919618.RAXAgf7Uco23iapLDeFKtUAcPnPmvxmIZZlbgE39IS5sk130_assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP919618.RAXAgf7Uco23iapLDeFKtUAcPnPmvxmIZZlbgE39IS5sk130_provenance.
- NP440156.RAPvyuMX2xI7ZOOgCDCr2iecDg9mY9C-Qgxh2evsMnfXA130_assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP440156.RAPvyuMX2xI7ZOOgCDCr2iecDg9mY9C-Qgxh2evsMnfXA130_provenance.
- NP666277.RAHurDMHrZtueBO0pWZhmhPk0Razt0_qal9MFebtgN7R4130_assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP666277.RAHurDMHrZtueBO0pWZhmhPk0Razt0_qal9MFebtgN7R4130_provenance.
- NP875114.RAwGu-sXp96GrZjS83sn5SZIp-plIbUtode-u-uVW38Mc130_assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP875114.RAwGu-sXp96GrZjS83sn5SZIp-plIbUtode-u-uVW38Mc130_provenance.
- NP618964.RAVcOyRJBwN8uXYSeQV51cYciaWaDnt04SK34h1p12Daw130_assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618964.RAVcOyRJBwN8uXYSeQV51cYciaWaDnt04SK34h1p12Daw130_provenance.
- NP862324.RA4bRqxNF1fcnoavF06hBTKMVmrlpUNPd45fvthDQAPQ4130_assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP862324.RA4bRqxNF1fcnoavF06hBTKMVmrlpUNPd45fvthDQAPQ4130_provenance.
- NP497594.RAwin_55G1c4e2uI30lLqRKpW7CI-pU7lg6VMKr7JAQxk130_assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP497594.RAwin_55G1c4e2uI30lLqRKpW7CI-pU7lg6VMKr7JAQxk130_provenance.
- NP497601.RARRoCgJ19WnBqi2mXGd_1cVQD40rcsbDmaW2cnZ_z8FE130_assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP497601.RARRoCgJ19WnBqi2mXGd_1cVQD40rcsbDmaW2cnZ_z8FE130_provenance.
- assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP497602.RAPcX1TvHEwvLEslBefLBNF55pgFLv9GwqfWmOj5QOacY130_assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP497602.RAPcX1TvHEwvLEslBefLBNF55pgFLv9GwqfWmOj5QOacY130_provenance.
- NP869506.RAjP26Kfj7KkJdu7KDd4vLRmoAncqeBMgpll2neDFoYso130_assertion description "[Using sensitive SYBR green methylation-specific PCR technology, we observed a respective 28% and 71% hypermethylation rate at the RASSF1a and MDR1 loci in benign prostate hyperplasia, which may represent early nonaggressive carcinogenesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP869506.RAjP26Kfj7KkJdu7KDd4vLRmoAncqeBMgpll2neDFoYso130_provenance.